Kale J, Osterlund EJ, Andrews DW (2017) Bcl-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25(1):65–80. https://doi.org/10.1038/cdd.2017.186
Article CAS PubMed PubMed Central Google Scholar
Shamas-Din A, Kale J, Leber B, Andrews DW (2013) Mechanisms of action of bcl-2 family proteins. Cold Spring Harb Perspect Biol 5(4):a008714. https://doi.org/10.1101/cshperspect.a008714
Article CAS PubMed PubMed Central Google Scholar
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Elmore SW (2013) ABT-199, a potent and selective bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202–208. https://doi.org/10.1038/nm.3048
Article CAS PubMed Google Scholar
Zhang X, Liu X, Zhou D, Zheng G (2020) Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future Med Chem 12(7):563–565. https://doi.org/10.4155/fmc-2020-0004
Article CAS PubMed Google Scholar
Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM (2011) Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909–16. https://doi.org/10.1200/JCO.2010.31.6208
Article CAS PubMed PubMed Central Google Scholar
He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D (2020) Proteolysis targeting chimeras (protacs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol 13(1):103–127. https://doi.org/10.1186/s13045-020-00924-z
Article PubMed PubMed Central Google Scholar
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D (2020) DT2216—a bcl-xl-specific degrader is highly active against bcl-xl-dependent T cell lymphomas. J Hematol Oncol 13(1):95–108. https://doi.org/10.1186/s13045-020-00928-9
Article CAS PubMed PubMed Central Google Scholar
Khan S, Zhang X, Lv D, Zhang Q, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand J, Pei J, Zhang W, Sharma A, Mccurdy C, Kuruvilla V, Baran N, Ferrando A, Kim Y, Rogojina A, Zhou D (2019) A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. https://doi.org/10.1038/s41591-019-0668-z
Article PubMed PubMed Central Google Scholar
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D (2022) Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216. Mol Cancer Ther 21(1):184–192. https://doi.org/10.1158/1535-7163.MCT-21-0474
Article CAS PubMed Google Scholar
Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D (2022) BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol 15(1):23. https://doi.org/10.1186/s13045-022-01241-3
Article CAS PubMed PubMed Central Google Scholar
Békés M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181–200. https://doi.org/10.1038/s41573-021-00371-6
Article CAS PubMed PubMed Central Google Scholar
Gao H, Sun X, Rao Y (2020) PROTAC Technology: opportunities and challenges. ACS Med Chem Lett 11(30):237–240. https://doi.org/10.1021/acsmedchemlett.9b00597
Article CAS PubMed PubMed Central Google Scholar
Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, Thompson CB (1995) (1995) Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 92(11):4763–4767. https://doi.org/10.1073/pnas.92.11.4763
Article CAS PubMed PubMed Central Google Scholar
Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A (2014) Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 4(9):1074–87. https://doi.org/10.1158/2159-8290.CD-14-0353
Article CAS PubMed PubMed Central Google Scholar
Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC (2008) Activation of the JNK pathway promotes phosphorylation and degradation of BimEL–a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 29(3):544–51. https://doi.org/10.1093/carcin/bgm294
Article CAS PubMed Google Scholar
Kolb R, De U, Khan S et al (2021) Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun 12:1281. https://doi.org/10.1038/s41467-021-21573-x
Article CAS PubMed PubMed Central Google Scholar
Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM (2019) Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood 133(6):566–575. https://doi.org/10.1182/blood-2018-07-865527
Article CAS PubMed PubMed Central Google Scholar
Follini E, Marchesini M, Roti G (2019) Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. Int J Mol Sci 20(12):3021. https://doi.org/10.3390/ijms20123021
Article CAS PubMed Central Google Scholar
Beesley A, Palmer ML, Ford J et al (2016) Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer 95:1537–1544. https://doi.org/10.1038/sj.bjc.6603447
Raetz EA, Teachey DT (2016) T-cell acute lymphoblastic leukemia. Hematology 2016(1):580–588. https://doi.org/10.1182/asheducation-2016.1.580
Article PubMed PubMed Central Google Scholar
Goossens S, Radaelli E, Blanchet O et al (2015) ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun 6:5794. https://doi.org/10.1038/ncomms6794
Article CAS PubMed Google Scholar
Lv D, Pal P, Liu X et al (2021) Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun 12:6896. https://doi.org/10.1038/s41467-021-27210-x
留言 (0)